Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Sodium sulfate, magnesium sulfate, and potassium chloride

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Sodium sulfate, magnesium sulfate, and potassium chloride key facts

Used for
SUTAB is indicated for the cleansing of the colon as a preparation for colonoscopy in adults. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
No generic listed by the FDA
Typical pharmacy cost
$6.72 per tablet (magnesium sulfate anhydrous 2.7 g · potassium chloride 2.25 g · sodium sulfate 17.75 g; NADAC)
Latest FDA recall
None listed

Sources: FDA label (October 8, 2026); FDA NDC Directory (November 13, 2026); CMS NADAC (November 11, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Sodium sulfate, magnesium sulfate, and potassium chloride used for?
The FDA-approved label (Sutab, Braintree Laboratories, Inc., October 8, 2026) says: “SUTAB is indicated for the cleansing of the colon as a preparation for colonoscopy in adults. SUTAB is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Sodium sulfate, magnesium sulfate, and potassium chloride?
The “Adverse Reactions” section of the FDA label (Sutab, Braintree Laboratories, Inc., October 8, 2026) begins: “The following serious or otherwise important adverse reactions for bowel preparations are described elsewhere in the labeling: Serious Fluid and Electrolyte Abnormalities [see Warnings and Precautions (5.1)] Cardiac Arrhythmias [see Warnings and Precautions (5.2)] Seizures [see Warnings and Precautions (5.3)] Patients with Risk of Renal Injury [see Warnings and Precautions (5.4)] Colonic Mucosal Ulceration and Ischemic Colitis [see Warnings and Precautions (5.5)] Patients with Significant Gastrointestinal Disease [see Warnings and Precautions (5.6)] Hypersensitivity Reactions [see Warnings and Precautions (5.7)] Risk of Gastrointestinal Complications with Ingestion of Desiccant [see Warnings and Precautions (5.8)] Most common gastrointestinal adverse reactions are nausea, abdominal distension, vomiting and upper abdominal pain.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Sodium sulfate, magnesium sulfate, and potassium chloride?
The “Drug Interactions” section of the FDA label (Sutab, Braintree Laboratories, Inc., October 8, 2026) begins: “Drugs that increase risk of fluid and electrolyte imbalance (7.1) 7.1 Drugs That May Increase Risks of Fluid and Electrolyte Abnormalities Use caution when prescribing SUTAB to patients taking medications that increase the risk of fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. 7.2 Potential for Reduced Drug Absorption SUTAB can reduce the absorption of other co-administered drugs [see Dosage and Administration (2.1)]: Administer oral medications at least one hour before starting each dose of SUTAB.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Sodium sulfate, magnesium sulfate, and potassium chloride have a boxed warning?
No. None of the 2 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Sodium sulfate, magnesium sulfate, and potassium chloride?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Sodium sulfate, magnesium sulfate, and potassium chloride been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Sodium sulfate, magnesium sulfate, and potassium chloride?
2 companies list prescription products of Sodium sulfate, magnesium sulfate, and potassium chloride in the FDA NDC Directory, including Braintree Laboratories, Inc. and Azurity Pharmaceuticals, Inc.

What Sodium sulfate, magnesium sulfate, and potassium chloride is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

SUTAB is indicated for the cleansing of the colon as a preparation for colonoscopy in adults. SUTAB is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.

— FDA label: Sutab, Braintree Laboratories, Inc., effective October 8, 2026. Read the full label on DailyMed →

Label quoted: the one for the most common form (tablet, oral), Sutab, Braintree Laboratories, Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

0 of 2 FDA labels for this medicine have a boxed warning.

Sodium sulfate, magnesium sulfate, and potassium chloride side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The following serious or otherwise important adverse reactions for bowel preparations are described elsewhere in the labeling: Serious Fluid and Electrolyte Abnormalities [see Warnings and Precautions (5.1)] Cardiac Arrhythmias [see Warnings and Precautions (5.2)] Seizures [see Warnings and Precautions (5.3)] Patients with Risk of Renal Injury [see Warnings and Precautions (5.4)] Colonic Mucosal Ulceration and Ischemic Colitis [see Warnings and Precautions (5.5)] Patients with Significant Gastrointestinal Disease [see Warnings and Precautions (5.6)] Hypersensitivity Reactions [see Warnings and Precautions (5.7)] Risk of Gastrointestinal Complications with Ingestion of Desiccant [see Warnings and Precautions (5.8)] Most common gastrointestinal adverse reactions are nausea, abdominal distension, vomiting and upper abdominal pain.

Read more of this section

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Braintree Laboratories, Inc. at 1-800-874-6756 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in clinical studies of another drug and may not reflect the rates observed in practice. The safety of SUTAB was evaluated in two randomized, parallel group, multicenter, investigator blinded clinical trials in 941 adult patients undergoing colonoscopy. The active comparators were polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, ascorbic acid and sodium ascorbate for oral solution in Study 1 and sodium picosulfate, magnesium oxide, and anhydrous citric acid for oral solution in Study 2 [see Clinical Studies (14)]. Adverse Gastrointestinal Reactions Reported by Symptom Questionnaire In Studies 1 and 2, patients were queried for selected gastrointestinal adverse reactions of stomach cramping (upper abdominal pain), stomach bloating (abdominal distention), nausea and vomiting using a standard questionnaire following completion of study drug and prior to colonoscopy on the day of colonoscopy. Patients reporting selected gastrointestinal symptom(s) rated the intensity as mild, moderate or severe. A total of 52% (287/552) of patients in Study 1 and 52% (202/389) in Study 2 reported at least one selected gastrointestinal adverse reaction when queried using the standard questionnaire. Tables 1 and 2 show results for each gastrointestinal adverse reaction reported by patients using the standard questionnaire, including severity. Table 1: Gastrointestinal Symptoms by Severity a From Symptom Questionnaire in Adult Patients Following Colon Cleansing and Prior to Colonoscopy – Study 1 b a Mild: barely noticeable, does not influence functioning causing no limitations of usual activities; Moderate: makes participant uncomfortable, influences functioning causing some limitations of usual activities; Severe: severe discomfort, treatment needed, severe and undesirable, causing inability to carry out usual activities b Study 1 was not designed to support comparative claims for SUTAB for the adverse reactions reported in this table. c Percentage represents n/N for patients who experienced each gastrointestinal adverse reaction on the symptom questionnaire based on the total number of patients per treatment arm.

— FDA label: Sutab, Braintree Laboratories, Inc., effective October 8, 2026. This is part of the section. Read the full label on DailyMed →

Sodium sulfate, magnesium sulfate, and potassium chloride drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

Drugs that increase risk of fluid and electrolyte imbalance (7.1) 7.1 Drugs That May Increase Risks of Fluid and Electrolyte Abnormalities Use caution when prescribing SUTAB to patients taking medications that increase the risk of fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. 7.2 Potential for Reduced Drug Absorption SUTAB can reduce the absorption of other co-administered drugs [see Dosage and Administration (2.1)]: Administer oral medications at least one hour before starting each dose of SUTAB.

Read more of this section

Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUTAB to avoid chelation with magnesium. 7.3 Stimulant Laxatives Concurrent use of stimulant laxatives and SUTAB may increase the risk of mucosal ulceration or ischemic colitis. Avoid use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) while taking SUTAB [see Warnings and Precautions (5.5)].

— FDA label: Sutab, Braintree Laboratories, Inc., effective October 8, 2026. Read the full label on DailyMed →

Sodium sulfate, magnesium sulfate, and potassium chloride dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

For complete information on preparation before colonoscopy and administration of the dosage regimen, see full prescribing information. (2.1, 2.2) Preparation and Administration (2.1) Administration of two doses (24 tablets) are required for a complete preparation for colonoscopy. SUTAB is supplied as two bottles each containing 12 tablets. Twelve (12) tablets are equivalent to one dose. Each SUTAB bottle contains a desiccant.

Read more of this section

Remove and discard the desiccant from both bottles the evening prior to the colonoscopy. Must consume water with each dose and an additional 32 ounces of water after each dose. Do not take other laxatives. Administer oral medications at least 1 hour before starting each dose of SUTAB. If taking tetracycline or fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, or penicillamine, take these medications at least 2 hours before and not less than 6 hours after administration of each dose. Recommended Split Dose (2-Day) Regimen (2.2) Day 1, Dose 1: On the Evening Prior to Colonoscopy Open 1 bottle of 12 tablets. Remove and discard the desiccant. Remove and discard the desiccant from the second bottle and close the bottle. Use the second bottle for the second dose on the morning of the colonoscopy. Fill the provided container with 16 ounces of water (up to the fill line). Swallow each tablet with a sip of water and drink the entire amount over 15 to 20 minutes. Approximately one hour after the last tablet is ingested, fill the provided container a second time with 16 ounces of water (up to the fill line) and drink the entire amount over 30 minutes. Approximately 30 minutes after finishing the second container of water, fill the provided container with 16 ounces of water (up to the fill line) and drink the entire amount over 30 minutes. Day 2, Dose 2: Morning of the Colonoscopy (5 to 8 hours prior to the colonoscopy and no sooner than 4 hours from starting Dose 1): Continue to consume only clear liquids until after the colonoscopy. Repeat Step 2 to Step 4 from Day 1, Dose 1. If patients experience preparation-related symptoms (e.g., nausea, bloating, cramping), pause or slow the rate of drinking the additional water until symptoms diminish. Complete all SUTAB tablets and water at least two hours prior to colonoscopy. 2.1 Important Preparation and Administration Instructions Correct fluid and electrolyte abnormalities before treatment with SUTAB [see Warnings and Precautions (5.1)] Administration of two doses of SUTAB (24 tablets) are required for a complete preparation for colonoscopy. SUTAB is supplied as two bottles each containing 12 tablets. Twelve (12) tablets are equivalent to one dose. Each SUTAB bottle contains a desiccant. Remove and discard the desiccant from both bottles of SUTAB the evening prior to the colonoscopy [see Dosage and Administration (2.2)]. Must consume water with each dose of SUTAB and an additional 32 ounces of water must be consumed after each dose [see Dosage and Administration (2.2) and Warnings and Precautions (5.1)]. Consume a low residue breakfast on the day before colonoscopy, followed by clear liquids up to 2 hours prior to colonoscopy. Do not drink milk or eat or drink anything colored red or purple.

— FDA label: Sutab, Braintree Laboratories, Inc., effective October 8, 2026. This is part of the section. Read the full label on DailyMed →

When Sodium sulfate, magnesium sulfate, and potassium chloride should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

SUTAB is contraindicated in the following conditions: Gastrointestinal obstruction or ileus [see Warnings and Precautions (5.6) Bowel Perforation [see Warnings and Precautions (5.6) Toxic colitis or toxic megacolon Gastric retention Hypersensitivity to any ingredient in SUTAB [see Warnings and Precautions (5.7) and Description (11)] Gastrointestinal obstruction or ileus (4, 5.6) Bowel perforation (4, 5.6) Toxic colitis or toxic megacolon (4) Gastric retention (4) Hypersensitivity to any ingredient in SUTAB (4, 5.7)

— FDA label: Sutab, Braintree Laboratories, Inc., effective October 8, 2026. Read the full label on DailyMed →

Sodium sulfate, magnesium sulfate, and potassium chloride overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

Overdosage of more than the recommended dose of SUTAB may lead to severe electrolyte disturbances, as well as dehydration and hypovolemia, with signs and symptoms of these disturbances [see Warnings and Precautions (5.1, 5.2, 5.3)]. Monitor for fluid and electrolyte disturbances and treat symptomatically.

— FDA label: Sutab, Braintree Laboratories, Inc., effective October 8, 2026. Read the full label on DailyMed →

Forms and how it is given

Dosage formsTablet
RouteOral
Prescription products2 in the FDA NDC Directory
Brand namesSutab

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Sodium sulfate, magnesium sulfate, and potassium chloride, by strength and form
Strength and formGeneric or brandPharmacies pay
magnesium sulfate anhydrous 2.7 g · potassium chloride 2.25 g · sodium sulfate 17.75 g
tablet
Brand: Sutab $6.72 per tablet

NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA213135
SUTAB
AzurityNovember 10, 2020 2, latest October 24, 2023
2023: Labeling · 2022: Labeling

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

SPL set ID of the quoted labeldddd2701-4d46-44de-a9f8-303d4dcceef7
FDA labels (SPL)2
FDA applicationsNDA213135
Active ingredients (FDA)MAGNESIUM SULFATE ANHYDROUS / POTASSIUM CHLORIDE / SODIUM SULFATE

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Sutab, Braintree Laboratories, Inc., effective October 8, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers